Amondys-45 (Casimersen) Patent Expiration, LOE Window & CMS Spending

Amondys-45 (Casimersen) by Sarepta Therape: Off-Patent Genericized (AB Competition), 0 AB generics, $185.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSarepta Therape
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$185.3M
2024 Medicare Part D Spend$14.1M
2024 Medicaid Spend$171.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sarepta Therapeutics across sibling Meru public-data platforms.